Time to stop talking about screening for diabetes?

Diabetic Medicine

Volumn 23, Issue 11, 2006, Pages 1163-1164

  Stephens, J W ^a   Williams, R ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DIAGNOSTIC APPROACH ROUTE; EDITORIAL; FOLLOW UP; HEALTH PROGRAM; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; UNITED KINGDOM;

DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HUMANS; MALE; MASS SCREENING; PREGNANCY; RISK FACTORS;

EID: 33750199610     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01997.x     Document Type: Editorial

References (17)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Lawrence J, Robinson A. Screening for diabetes in general practice. Prev Cardiol 2003; 6: 78-84.
3. Wingard DL, Barrett-Connor EL, Scheidt-Nave C, McPhillips JB. Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study. Diabetes Care 1993; 16: 1022-1025.
4. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care 2000; 23: 1563-1580.
5. Colagiuri S, Hussain Z, Zimmet P, Cameron A, Shaw J. Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience. Diabetes Care 2004; 27: 367-371.
6. Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality. Data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005; 28: 2626-2632.
7. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26: 725-731.
8. Taylor CA, Keim KS, Fuqua DR, Johnson CA. A diabetes prevention assessment tool for American Indians. Prev Chronic Dis 2005; 2: A06.
9. British Diabetes Association. Recommendations for the Management of Diabetes in Primary Care. London: BDA 1997.
10. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997; 46: 701-710.
11. Vaccaro O, Ruffa G, Imperatore G, Iovino V, Rivellese AA, Riccardi G. Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care 1999; 22: 1490-1493.
12. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
13. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
14. Amereican Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases. The prevention or delay of type 2 diabetes. Diabetes Care 2002; 25: 742-749.
15. Paterson KR. Population screening for diabetes mellitus. Professional Advisory Committee of the British Diabetic Association. Diabet Med 1993; 10: 777-781.
16. Sievenpiper JL, Leiter LA, Vuksan V. Intrasubject coefficient-of- variation corresponds to diagnostic reproducibility in diabetes screening. Can J Diabetes 2002; 26: 105-112.
17. Schousboe K, Henriksen JE, Kyvik KO, Sorensen TI, Hyltoft Petersen P. Reproducibility of S-insulin and B-glucose responses in two identical oral glucose tolerance tests. Scand J Clin Lab Invest 2002; 62: 623-630.